Suga J, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Sakurai M, Sano T, Tamura T, Hoshi A
Jpn J Clin Oncol. 1986 Jun;16(2):147-51. doi: 10.1093/oxfordjournals.jjco.a039131.
A phase II study of mitoxantrone was performed in 24 patients with non-small cell lung cancer (NSCLC). Mitoxantrone was administered by intravenous drip infusion of 12 mg/m2 every three weeks. There were no responders among the 21 evaluable patients including five patients without prior therapy. The major hematological toxic effect was leukocytopenia. Thrombocytopenia and decrease in hemoglobin were slight. A change in the electrocardiogram was observed in one patient and one patient experienced cardiogenic shock. Mitoxantrone is not acceptable for the treatment of NSCLC because of its low antitumor activity, and careful observation is needed for administration of this agent to patients with pre-existing risk factors, such as prior anthracycline exposure, mediastinal radiation or underlying cardiovascular disease.
对24例非小细胞肺癌（NSCLC）患者进行了米托蒽醌的II期研究。米托蒽醌通过静脉滴注给药，剂量为每三周12mg/m²。在包括5例未经先前治疗的患者在内的21例可评估患者中无反应者。主要血液学毒性作用为白细胞减少。血小板减少和血红蛋白降低轻微。1例患者观察到心电图改变，1例患者发生心源性休克。由于米托蒽醌抗肿瘤活性低，故不适合用于NSCLC的治疗，对于有先前蒽环类药物暴露、纵隔放疗或潜在心血管疾病等既往危险因素的患者，给药时需仔细观察。
